MIRA Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $29.8M
- Price
- $0.71
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.25%
- Volume
- 67.7K
About
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
Quick stats
Shares outstanding42.0M
Computed float35.0M
Float / shares83.3%
Key info
SectorHealthcare
IndustryDrug Manufacturers - General
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001904286
AI Summary
AI-generated1/14
standardbullishclinical trial
MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
MIRA Pharmaceuticals advanced Ketamir-2 into Phase 2a for chemotherapy-induced peripheral neuropathy, submitting the protocol for Institutional Review Board review at a leading cancer research institution after incorporating FDA feedback; site initiation is targeted for the first quarter of 2027.
The randomized, double-blind, placebo-controlled crossover study will test oral Ketamir-2 at 300 mg and 600 mg against placebo in adults with moderate-to-severe persistent CIPN, marking the drug's first evaluation in patients after a Phase 1 program that showed no serious adverse events or dose-limiting toxicities.
There are currently no FDA-approved therapies specifically indicated for CIPN, and MIRA views positive Phase 2a data as a potential entry point into the broader neuropathic pain market; Ketamir-2 is an oral NMDA receptor modulator that is not classified as a controlled substance by the DEA.
MIRA will present Phase 1 data in an oral session in Tokyo on October 5-6, 2026, and will participate in BioJapan as licensing and strategic partnership discussions around Ketamir-2 continue.
Red flags
- No patient efficacy data yet -- Phase 2a is the first clinical test in a CIPN population and readout is distant
- Site initiation not expected until Q1 2027 and remains subject to IRB review and site activation, creating timeline slippage risk
- Pre-revenue clinical-stage biotech; forward-looking statements explicitly cite financing needs, implying ongoing dilution risk